Which peptides are studied in relation to proteostasis?
A research-supply survey of the peptide and protein targets examined in proteostasis literature — chaperonins, mitochondrial proteases, NAD+ biosynthesis enzymes, and autophagy regulators — with notes on which findings a
Proteostasis research does not centre on a single peptide. The literature examined here covers several distinct molecular classes: the eukaryotic chaperonin CCT/TRiC, a multi-subunit ATP-dependent folding machine; the mitochondrial serine protease HtrA2 (also written HTRA2/OMI); the mitophagy regulator Pink1; the NAD+ biosynthesis enzyme nicotinamide mononucleotide adenylyltransferase 1 (NMNAT-1), the major nuclear isoform of the mammalian NMNAT family; and the autophagy machinery operating in hypothalamic arcuate nucleus neurons. These are proteins and protein complexes rather than short synthetic peptides, and the evidence block does not supply sequence, formula or molecular weight values for any of them.
The work converges on two connected systems: the ubiquitin-proteasome and autophagy-lysosomal degradation pathways, and the mitochondrial quality-control (mtQC) axis that couples mitochondrial proteases and mitophagy to nuclear stress signalling [1][6].
Research Studies
CCT/TRiC and therapy-induced senescence in glioblastoma multiforme
Glioblastoma multiforme is described as chaperone dependent, relying on proteostasis networks for growth, invasion and treatment resistance. Standard therapy — resection, radiotherapy, temozolomide — drives many GBM cells into therapy-induced senescence, a state of permanent proliferation arrest with high metabolic activity and a senescence-associated secretory phenotype. Persistence of those cells is proposed to alter the microenvironment and support recurrence. The eukaryotic chaperonin CCT/TRiC is positioned within this chaperone-dependence framework [5].
HtrA2, Chop and Pink1 in DNA damage-induced senescence
Mouse embryonic fibroblasts deficient in the mitochondrial protease HtrA2, the transcription factor Chop, or the mitophagy regulator Pink1 were exposed to three mechanistically distinct genotoxic challenges to test how mtQC and stress signalling shape senescence induction [6]. This is an in vitro mouse-cell model; the findings are not human data.
NMNAT-1 and NAD+ homeostasis in neuroprotection and aging
NAD+ supports redox reactions, DNA repair, chromatin regulation, stress adaptation, inflammation and neuronal maintenance. Age-associated NAD+ decline has been implicated in brain aging and neurodegenerative disorders, though the causal node and limiting compartment differ across tissues and disease states. NMNAT-1 catalyses the final step in NAD+ biosynthesis, and direct human genetic evidence establishes it as a causal gene in inherited axon degeneration [4].
Astrocytic proteostasis failure in Parkinson's disease
A system-level model reframes Parkinson's disease as a multicellular failure of the neuroglial unit rather than a purely neuronal disorder. In this model, pathological alpha-synuclein triggers a cycle of astrocytic failure that includes impaired proteostasis via the ubiquitin-proteasome and autophagy-lysosomal pathways, glymphatic collapse linked to aquaporin-4 depolarisation, and neuroinflammation involving microglial crosstalk and NLRP3 inflammasome activation [1].
Circadian clock genes and proteostasis in Alzheimer's disease
Mechanistic studies in this review suggest interactions between core clock genes and neurodegenerative cascades involving oxidative stress, neuroinflammation, glial reactivity and proteostasis. Circadian-regulated pathways discussed include BMAL1-SIRT1 and NF-kappaB-NLRP3 signalling [7].
Autophagy in hypothalamic POMC and AgRP neurons
Within the arcuate nucleus, autophagy is reported to exert divergent metabolic effects in the two principal appetit-regulatory neuronal populations, in a model linking hypothalamic nutrient sensing, leptin responsiveness and intracellular quality control [9].
Mitochondrial quality control in autoimmune disease
Evidence reviewed in this context highlights mitochondrial quality control as a node relevant to cell type-specific metabolic vulnerability in heterogeneous autoimmune diseases, where single-pathway immunosuppression has limited efficacy and substantial toxicity [11].
Environmental toxin exposure and App/Tau homeostasis
Human neuroblastoma SH-SY5Y cells treated with low-dose T-2 toxin (6 nM, 24 h) were profiled for Alzheimer's-relevant protein changes alongside transcriptomic, circadian and senescence readouts, reporting disruption of App/Tau homeostasis via circadian-p53-senescence crosstalk [12]. This is a cell-culture finding.
Comparative summary of models and evidence tiers
| Target | Model system | Evidence tier |
|---|---|---|
| CCT/TRiC | Glioblastoma multiforme | Review-level, tumour context [5] |
| HtrA2, Chop, Pink1 | Mouse embryonic fibroblasts | In vitro, mouse cells [6] |
| NMNAT-1 | Human genetic evidence | Causal gene in inherited axon degeneration [4] |
| Astrocytic proteostasis machinery | Parkinson's disease | System-level model, review [1] |
| Clock genes, BMAL1-SIRT1 | Alzheimer's disease | Mechanistic studies, review [7] |
| Autophagy in POMC/AgRP neurons | Arcuate nucleus | Review [9] |
| App/Tau | SH-SY5Y human neuroblastoma cells | In vitro, 6 nM T-2 toxin, 24 h [12] |
Adjacent contexts
Proteostasis also appears in reviews of bone aging, where degeneration is described across molecular, cellular, tissue and system levels [2]; in uremic protein-energy wasting, where systemic anabolic resistance is proposed to limit nutritional intervention [3]; in plant salinity tolerance, where cellular protectors maintain homeostasis under osmotic and ionic stress [8]; and in Parkinson's disease therapeutic repurposing surveys [10].
If you are reading this for personal health reasons
The materials described here are sold for laboratory research only. We do not provide dosing, administration or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Convergent Astrocytic Failure in Parkinson's Disease: A System-Level Model of Pathogenesis and Treatment
- [2] Bone aging: a paradigm of multiscale degeneration and targeted rejuvenation
- [3] Perspectives on the Nutritional Paradox in Uremia: A "Sensitize-Then-Feed" Framework for Protein-Energy Wasting
- [4] Nicotinamide Mononucleotide Adenylyltransferase 1 and NAD+ Homeostasis in Neuroprotection and Aging
- [5] From protection to progression: How CCT/TRiC shapes therapy-induced senescence in glioblastoma multiforme
- [6] Impaired mitochondrial quality control and stress signalling machinery modulate senescence induction by genotoxic challenge
- [7] Circadian rhythms and chronotherapy in Alzheimer's disease: Mechanisms and therapeutic implications
- [8] Role of primary protectors of plant cells in salinity tolerance: molecular mechanisms and adaptive strategies
- [9] Autophagy in hypothalamic POMC and AgRP neurons: mechanisms and therapeutic implications for obesity
- [10] Therapeutics candidates and repurposing strategies to target parkinson's disease pathology: current evidence and future directions
- [11] Reprogramming Autoimmune Immunity via Mitochondrial Quality Control: Mechanisms, Biomarkers, and Windows for Intervention
- [12] T-2 toxin disrupts Alzheimer's-relevant App/Tau homeostasis via circadian-p53-senescence crosstalk: Evidence from human neuroblastoma cells